Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Mulu, Andargachew ^a,b   Liebert, Uwe G ^b   Maier, Melanie ^b  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antiretroviral; CD4 T cells; Ethiopia; HIV drug resistance; HIV viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EFFICACY; ETHIOPIA; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; TREATMENT RESPONSE; VIREMIA; VIRUS INHIBITION; CD4+ T LYMPHOCYTE; GENETICS; GENOTYPE; HIV INFECTIONS; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; ETHIOPIA; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; VIREMIA;

EID: 84892379491     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-28     Document Type: Article

References (41)

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups.
2. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M, Antiretroviral Therapy Cohort Collaboration Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21(9):1185-1197. Antiretroviral Therapy Cohort Collaboration.
3. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DR, South Africa Resistance Cohort Study Team Prevalence of HIV-1 drug resistance after failure of a first line HAART regimen in Kwazulu Natal, South Africa. Clin Infect Dis 2008, 46:1589-1597. South Africa Resistance Cohort Study Team.
4. World Health Organisation Working Document on Monitoring and Evaluating of National ART Programmes in the Rapid Scale up to 3 by 5 2003, Geneva, http://www.who.int/3by5/, World Health Organisation.
5. World Health Organization Towards universal access: Scaling up priority HIV/AIDS intervention in health sector 2008, Geneva, http://www.who.int/hiv/pub/, World Health Organization.
6. Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, Piroj W, Tiensuwan M, Chantratita W. Surveillance of genotype resistance mutation in chronic HIV-1 treated individuals after completion of the national access to ART program in Thailand. Infection 2007, 35:81-88.
7. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR. Adherence to ART in sub-Saharan Africa and North America: a meta analysis. JAMA 2006, 296:679-690.
8. Tessema B, Biadglegne F, Mulu A, Getachew A, Emmrich F, Sack U. Magnitude and determinants of non adherence and non readiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study. AIDS Res Ther 2010, 7:2. doi:10.1186/1742-6405-7-2.
9. Ivers LC, Kendrick D, Doucette K. Efficacy of ART programs in resource poor settings: a meta analysis of the publicised literature. Clin Infect Dis 2005, 41:217-224.
10. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008, 47:712-722.
11. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005, 19:487-494.
12. Adjé C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respess R, Wiktor SZ, Chorba T, Nkengasong JN, UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire High prevalence of genotypic and phenotypic HIV-1 drug resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001, 26:501-506. UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire.
13. Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, Delaporte E. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002, 29:165-168.
14. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004, 20:355-364.
15. Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET, Haldar B, Powell RL, Jarido V, Hewlett IK, Nyambi PN. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J Med Virol 2010, 82:187-196.
16. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005, 19:2141-2148.
17. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005, 19:2109-2116.
18. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1 related immunodeficiency and age predict the long-term CD4+ T lymphocyte response to potent antiretroviral therapy. AIDS 2002, 16:359-367.
19. García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. Long-term CD4+ T-cell response to HHART according to baseline CD4+ T cell count. J Acquir Immune Defic Syndr 2004, 36:702-713.
20. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, Montaner JS. Discordant Immunologic and Virologic responses to HHART are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005, 40:288-293.
21. Guidelines for Paediatric HIV/AIDS Care and Treatment in Ethiopia. Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health 2007, http://www.etharc.org.
22. Guidelines for management of opportunistic infections and anti retroviral treatment in adolescents and adults in Ethiopia. Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health 2007, http://www.etharc.org.
23. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents WHO 2010, Geneva, http://www.who.int/hiv/pub/arv/adult2010/en/, World Health Organization.
24. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008, S2:S15-S23.
25. Drummond AJ, Ashton B, Buxton S, Cheung M, Cooper A, Duran C, et al. Geneious v5.4 2011, http://www.geneious.com.
26. Johannessen A, Naman E, Kivuyo S, Kasubi M, Holberg-Petersen M, Matee M. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009, 108:1-8.
27. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ 2013, 91:377-385.
28. Vaz P, Augusto O, Bila D, Macassa E, Vubil A, Jani IV, Pillon R, Sandstrom P, Sutherland D, Giaquinto C, Jordan MR, Bertagnolio S. Surveillance of HIV Drug Resistance in Children Receiving Antiretroviral Therapy: a Pilot Study of the World Health Organization's Generic Protocol in Maputo, Mozambique. Clin Infect Dis 2012, S4:S369-S374.
29. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV-1 drug resistance detection. Clin Infect Dis 2010, 50:98-105.
30. Auvert B, Males S, Puren A, Taljaard D, Carael M, Williams B. Can HAART reduce the spread of HIV? A study in a township of South Africa. J Acquir Immune Defic Syndr 2004, 36:613-621.
31. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, , et al. iPrEx Study Team Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599. iPrEx Study Team.
32. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. CAPRISA 004 Trial Group.
33. Kassaye K, Amberbir A, Getachew B, Mussema Y. A historical overview of traditional medicine practices and policy in Ethiopia. Ethiop J Health Dev 2006, 20:127-134.
34. Lee SA, Hong SK, Suh CI, Oh MH, Park JH, Choi BW, Park SW, Paik SY. Anti-HIV-1 Efficacy of Extracts from Medicinal Plants. J Microbiology 2010, 48:249-252.
35. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group CD4+ T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003, 163:2187-2195. Swiss HIV Cohort Study Group.
36. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN, PLATO Collaboration Predictors of trend in CD4+ positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004, 364:51-62. PLATO Collaboration.
37. Battegay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006, 6:280-287.
38. Messele T, Abdulkadir M, Fontanet AL, Petros B, Hamann D, Koot M, Roos MT, Schellekens PT, Miedema F, de Wit TF R. Reduced naive and increased activated CD4+ and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol 1999, 115:443-450.
39. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, Fontanet AL, de Wit TF R. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol 1999, 6:410-414.
40. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe CY C, Nabatanzi R, Kamya RM, Cao H. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011, 11:43.
41. Tsegaye A, Wolday D, Otto S, Petros B, Assefa T, Alebachew T, Hailu E, Adugna F, Measho W, Dorigo W, Fontanet AL, van Baarle D, Miedema F. Immunophenotyping of blood lymphocytes at birth, during childhood, and during adulthood in HIV-1-uninfected Ethiopians. Clin Immunol 2003, 109:338-346.